[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334590-105":3,"doc-detail-334590-en":81,"detail-sidebar-cat-0-en-105":99},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-progress-and-prospects-of-immune-cell-therapy-for-the-treatment-of-cancer-article-volume-33-1-to-20","The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer - Article - Volume 33 - 1 to 20","","Immune cell therapy is a transformative cancer treatment that uses living immune cells as therapeutic agents. Unlike conventional drugs, these “living drugs” are often customized and require advanced manufacturing, with CAR-T therapies driving major interest for hematologic cancers while solid-tumor efficacy remains limited. Alternative approaches such as TIL, CIK, dendritic cell vaccines, and DC/CIK leverage natural immune defense mechanisms and may show fewer side effects. Higher-manipulation and higher-risk platforms—including CAR-T, TCR-T, CAR-NK, and CAR-macrophages—are discussed alongside advances in mechanisms, product design, and technology innovations, supporting analysis of advantages, clinical transformation risks, and future application prospects.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-progress-and-prospects-of-immune-cell-therapy-for-the-treatment-of-cancer-article-volume-33-1-to-20/334590/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-progress-and-prospects-of-immune-cell-therapy-for-the-treatment-of-cancer-article-volume-33-1-to-20/334590.png","ImageObject",300,407,{"name":42,"@type":43},"Anda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is immune cell therapy, and how does it differ from traditional drugs?","Question",{"text":63,"@type":64},"Immune cell therapy uses living immune cells as therapeutic reagents for cancer. These “living drugs” are customized and rely on advanced manufacturing rather than the small-molecule or biologic drug model.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why are CAR-T therapies less effective for solid tumors compared with hematologic malignancies?",{"text":68,"@type":64},"The document notes that CAR-T has received substantial attention for hematologic malignancies, but effectiveness in solid tumors is often restricted. This limitation has driven development of alternative immune cell therapies.",{"name":70,"@type":61,"acceptedAnswer":71},"What immune cell therapy options are described as lower-side-effect approaches?",{"text":72,"@type":64},"Tumor-infiltrating lymphocytes (TIL), cytokine-induced killer (CIK) cell therapy, dendritic cell (DC) vaccines, and DC/CIK cell therapy are designed to target and eliminate cancer using natural defense mechanisms and are described as usually having fewer side effects or risks.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334590,1790028217,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":4},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297",8,"The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer  \nCell Transplantation Volume 33: 1–20  \n© The Author(s) 2024  \nArticle reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/09636897241231892](DOI: 10.1177/09636897241231892)[ ](DOI: 10.1177/09636897241231892)[journals.sagepub.com/home/cll](journals.sagepub.com/home/cll)  \nJia Han 1, Bowen Zhang 1, Senyu Zheng 1,2, Yuan Jiang 1,  \nXiaopeng Zhang3, and Kaiyun Mao 1  \nAbstract  \nImmune cell therapy as a revolutionary treatment modality, significantly transformed cancer care. It is a specialized form of immunotherapy that utilizes living immune cells as therapeutic reagents for the treatment of cancer. Unlike traditional drugs, cell therapies are considered “living drugs,” and these products are currently customized and require advanced manufacturing techniques. Although chimeric antigen receptor (CAR)-T cell therapies have received tremendous attention in the industry regarding the treatment of hematologic malignancies, their effectiveness in treating solid tumors is often restricted, leading to the emergence of alternative immune cell therapies. Tumor-infiltrating lymphocytes (TIL) cell therapy, cytokine-induced killer (CIK) cell therapy, dendritic cell (DC) vaccines, and DC/CIK cell therapy are designed to use the body’s natural defense mechanisms to target and eliminate cancer cells, and usually have fewer side effects or risks. On the other hand, cell therapies, such as chimeric antigen receptor-T (CAR-T) cell, T cell receptor (TCR)-T, chimeric antigen receptor-natural killer (CAR-NK), or CAR-macrophages (CAR-M) typically utilize either autologous stem cells, allogeneic or xenogeneic cells, or genetically modified cells, which require higher levels of manipulation and are considered high risk. These high-risk cell therapies typically hold special characteristics in tumor targeting and signal transduction, triggering new anti-tumor immune responses. Recently, significant advances have been achieved in both basic and clinical researches on anti-tumor mechanisms, cell therapy product designs, and technological innovations. With swift technological integration and a high innovation landscape, key future development directions have emerged. To meet the demands of cell therapy technological advancements in treating cancer, we comprehensively and systematically investigate the technological innovation and clinical progress of immune cell therapies in this study. Based on the therapeutic mechanisms and methodological features of immune cell therapies, we analyzed the main technical advantages and clinical transformation risks associated with these therapies. We also analyzed and forecasted the application prospects, providing references for relevant enterprises with the necessary information to make informed decisions regarding their R&D direction selection.  \nKeywords  \nimmune cell therapy, cellular immunotherapy, cancer, CAR, adoptive cellular therapy  \nIntroduction  \nCancer is a systemic disease that exploits multiple escape mechanisms to evade anti-cancer immunity1 and significantly change the function and composition of the immune system as a whole2. The evolution of anti-cancer therapies spans over a hundred years, with an ever-increasing efficacy and specificity in eliminating cancer cells while minimizing damage to healthy tissues. Toward this objective, immune cell therapy stands out among the existing approaches as a game-changing solution. In 2017, the Food and Drug Administration (FDA) approved two chimeric antigen receptor-T (CAR-T) cell therapies, axicabtagene ciloleucel (Yescarta)3 from Kite Pharm and tisagenlecleucel (Kymriah)4 from Novartis, for the treatment of lymphoma5. These approvals marked a significant milestone for the accelerating development of anti-cancer treatments.  \n1 Shanghai Information Center for Life Sciences, Shanghai Institute of Nutrit","cbCaibiLmJwZnLMY","https://ap.wps.com/l/cbCaibiLmJwZnLMY","pdf",1784367,20,"English","# Abstract\n# Introduction","[{\"question\":\"What is immune cell therapy, and how does it differ from traditional drugs?\",\"answer\":\"Immune cell therapy uses living immune cells as therapeutic reagents for cancer. These “living drugs” are customized and rely on advanced manufacturing rather than the small-molecule or biologic drug model.\"},{\"question\":\"Why are CAR-T therapies less effective for solid tumors compared with hematologic malignancies?\",\"answer\":\"The document notes that CAR-T has received substantial attention for hematologic malignancies, but effectiveness in solid tumors is often restricted. This limitation has driven development of alternative immune cell therapies.\"},{\"question\":\"What immune cell therapy options are described as lower-side-effect approaches?\",\"answer\":\"Tumor-infiltrating lymphocytes (TIL), cytokine-induced killer (CIK) cell therapy, dendritic cell (DC) vaccines, and DC/CIK cell therapy are designed to target and eliminate cancer using natural defense mechanisms and are described as usually having fewer side effects or risks.\"}]","The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer - Article - Volume 33 - 1 to 20 | PDF",1790007376,50,{"code":4,"msg":82,"data":100},[101,105,109,113,118,122,127,130,134,137,141],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":110,"show_sort_weight":111,"slug":112},"Exam",70,"exam",{"id":114,"doc_module":4,"doc_module_name":25,"category_name":115,"show_sort_weight":116,"slug":117},5,"Comic",60,"comic",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":98,"slug":121},6,"Technology","technology",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":125,"slug":126},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":128,"slug":129},30,"research-report",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":92,"slug":133},9,"Religion & Spirituality","religion-spirituality",{"id":92,"doc_module":4,"doc_module_name":25,"category_name":135,"show_sort_weight":92,"slug":136},"World Cup","world-cup",{"id":138,"doc_module":4,"doc_module_name":25,"category_name":139,"show_sort_weight":138,"slug":140},10,"Lifestyle","lifestyle",{"id":142,"doc_module":4,"doc_module_name":25,"category_name":143,"show_sort_weight":114,"slug":144},19,"General","general"]